In a recent trial conducted by Ventyx, the company has revealed positive results for its experimental drug, VTX002, in the treatment of ulcerative colitis. The clinical remission rate for the treatment was found to be 17%, which is within the previously projected range of 15% to 25%. Despite being at the lower end of the range, this result demonstrates the effectiveness of VTX002 and puts it on par with competing treatments.
As a result of this news, the company’s shares experienced a significant drop of 19%, trading at $24.22 in after-hours trading. This reaction from investors is likely due to the expectation of higher remission rates initially set by the guidance. Despite this setback, Ventyx remains hopeful that further research and development will yield improved results for the treatment of ulcerative colitis.
Lexicon Pharmaceuticals Secures Preferred Formulary Status for Heart Failure Treatment
Lexicon Pharmaceuticals has achieved a significant milestone by securing preferred formulary status for their heart failure treatment, Inpefa. This status has been granted by Express Scripts specifically for Medicare patients starting from November 1st.
Inpefa received approval from the Food and Drug Administration in May, and this latest development further solidifies its position in the market. Following the announcement, Lexicon Pharmaceuticals observed a notable increase in their shares, which rose by 15% to $1.15 in after-hours trading.
The preferred formulary status will undoubtedly enhance accessibility to Inpefa, ensuring that Medicare patients have easier access to this vital treatment for heart failure.
Positive Interim Data Shows Promise for Multiple Sclerosis Treatment
Encouraging interim data has been released by Immunic from their Phase 2 trial investigating a potential treatment for progressive multiple sclerosis (MS). The data indicates that patients receiving Immunic’s treatment experienced lower levels of a key biomarker associated with MS compared to those who received the placebo.
This significant finding has generated a surge of positivity and optimism, reflected in Immunic’s shares, which soared by 49% to $2.37 during after-hours trading. The results suggest that Immunic’s treatment may have the potential to positively impact the lives of those living with progressive multiple sclerosis.
Further research and analysis will be conducted to validate these promising results and determine the future potential of this treatment.